SOPHiA GENETICS (NASDAQ:SOPH) Sees Large Volume Increase – Here’s What Happened

Shares of SOPHiA GENETICS SA (NASDAQ:SOPH) saw an uptick in trading volume on Tuesday . 229,338 shares traded hands during trading, an increase of 31% from the previous session’s volume of 174,682 shares.The stock last traded at $6.2430 and had previously closed at $5.98.

Wall Street Analyst Weigh In

Several brokerages recently weighed in on SOPH. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of SOPHiA GENETICS in a research report on Tuesday, April 21st. BTIG Research restated a “buy” rating and issued a $8.00 target price on shares of SOPHiA GENETICS in a report on Monday, June 15th. Two equities research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. According to MarketBeat, the company presently has a consensus rating of “Hold” and a consensus price target of $7.50.

SOPHiA GENETICS Stock Performance

The company’s 50 day simple moving average is $5.09 and its 200 day simple moving average is $4.93. The company has a debt-to-equity ratio of 1.05, a quick ratio of 1.90 and a current ratio of 2.06. The stock has a market cap of $510.08 million, a PE ratio of -11.74 and a beta of 0.98.

SOPHiA GENETICS (NASDAQ:SOPH) last announced its earnings results on Tuesday, May 5th. The company reported ($0.27) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.23) by ($0.04). The business had revenue of $21.69 million during the quarter, compared to analysts’ expectations of $20.40 million. SOPHiA GENETICS had a negative return on equity of 62.74% and a negative net margin of 44.48%.

Insider Buying and Selling at SOPHiA GENETICS

In other news, CTO Abhimanyu Verma sold 6,944 shares of the firm’s stock in a transaction on Thursday, June 25th. The stock was sold at an average price of $5.51, for a total transaction of $38,261.44. Following the completion of the sale, the chief technology officer directly owned 197,456 shares of the company’s stock, valued at $1,087,982.56. This trade represents a 3.40% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, insider Philippe Menu sold 5,000 shares of SOPHiA GENETICS stock in a transaction on Thursday, June 25th. The stock was sold at an average price of $5.50, for a total value of $27,500.00. Following the sale, the insider owned 240,780 shares in the company, valued at $1,324,290. The trade was a 2.03% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 263,185 shares of company stock worth $1,341,645 in the last quarter. 4.88% of the stock is currently owned by company insiders.

Institutional Trading of SOPHiA GENETICS

Hedge funds have recently added to or reduced their stakes in the stock. Perkins Capital Management Inc. purchased a new position in SOPHiA GENETICS in the fourth quarter valued at about $49,000. Squarepoint Ops LLC bought a new stake in shares of SOPHiA GENETICS in the 3rd quarter worth approximately $49,000. First Dallas Securities Inc. bought a new stake in shares of SOPHiA GENETICS in the 1st quarter worth approximately $50,000. Quadrature Capital Ltd purchased a new position in SOPHiA GENETICS in the fourth quarter valued at approximately $54,000. Finally, XTX Topco Ltd purchased a new position in SOPHiA GENETICS in the fourth quarter valued at approximately $55,000. Institutional investors own 31.59% of the company’s stock.

SOPHiA GENETICS Company Profile

SOPHiA GENETICS SA is a data-driven medicine company founded in 2011 and headquartered in La Tène, Switzerland. The firm develops and operates a cloud-native software platform designed to standardize and analyze complex genomic and radiomic data. Its core offering, the SOPHiA DDM™ platform, leverages artificial intelligence and machine learning algorithms to help healthcare institutions, laboratories and biopharmaceutical partners derive actionable insights from next-generation sequencing and medical imaging datasets.

The SOPHiA DDM™ platform supports a range of clinical applications, including oncology, hereditary diseases and rare genetic disorders.